Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$54.2 million.

  • Ocular Therapeutix's Cash from Operations fell 3758.65% to -$54.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$204.9 million, marking a year-over-year decrease of 5212.92%. This contributed to the annual value of -$204.9 million for FY2025, which is 5212.92% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Cash from Operations stood at -$54.2 million, which was down 3758.65% from -$50.7 million recorded in Q3 2025.
  • Ocular Therapeutix's 5-year Cash from Operations high stood at -$7.7 million for Q3 2023, and its period low was -$55.2 million during Q2 2025.
  • Its 5-year average for Cash from Operations is -$26.7 million, with a median of -$20.1 million in 2021.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 4577.18% in 2022, then plummeted by 37282.72% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Cash from Operations (Quarter) stood at -$15.2 million in 2021, then decreased by 11.91% to -$17.0 million in 2022, then tumbled by 32.41% to -$22.5 million in 2023, then crashed by 75.6% to -$39.4 million in 2024, then tumbled by 37.59% to -$54.2 million in 2025.
  • Its Cash from Operations stands at -$54.2 million for Q4 2025, versus -$50.7 million for Q3 2025 and -$55.2 million for Q2 2025.